Virax Biolabs Group (Virax Biolabs Group) Issuance of Stock

: $7.10 Mil (TTM As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

Virax Biolabs Group's Issuance of Stock for the six months ended in Sep. 2023 was $0.00 Mil.

Virax Biolabs Group's Issuance of Stock for the trailing twelve months (TTM) ended in Sep. 2023 was $7.10 Mil.

Virax Biolabs Group Issuance of Stock Historical Data

The historical data trend for Virax Biolabs Group's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Issuance of Stock

0.52

13.65

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Issuance of Stock				-	-	6.56	7.10	-

Virax Biolabs Group Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $7.10 Mil.

Virax Biolabs Group Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Issuance of Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.